このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発/難治性末梢性 T 細胞リンパ腫 (VALENTINE-PTCL01) のための Zeste Homolog (EZH) 1/2 二重阻害剤のエンハンサーである Valemetostat Tosylate (DS-3201b)

2026年10月23日 更新者:Daiichi Sankyo

再発/難治性末梢性T細胞リンパ腫(VALENTINE-PTCL01)の被験者におけるバレメトスタットトシレート単剤療法の単群第2相試験

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

This study was designed to evaluate the efficacy and safety of valemetostat tosylate monotherapy. The primary objective will evaluate objective response rate of valemetostat tosylate monotherapy as measured by blinded independent central review (BICR) in relapsed/refractory peripheral T-cell lymphoma.

研究の種類

介入

入学 (実際)

155

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Duarte、California、アメリカ、91010
        • City Of Hope National Medical Center
      • Palo Alto、California、アメリカ、94304
        • Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY
      • San Francisco、California、アメリカ、94143
        • University of California San Francisco
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • University Of Colorado Cancer Center
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • Emory University Hospital - Winship Cancer Institute
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • Northwestern University - Feinberg School of Medicine
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02115
        • Dana Farber Cancer Institute
    • Minnesota
      • Rochester、Minnesota、アメリカ、55901
        • Mayo Clinic - Rochester
    • Missouri
      • St Louis、Missouri、アメリカ、63110
        • Washington University School of Medicine
    • New Jersey
      • Hackensack、New Jersey、アメリカ、07601
        • Hackensack University Medical Center - John Theurer Cancer Center
    • New York
      • New York、New York、アメリカ、10065
        • Weill Cornell Medicine
      • New York、New York、アメリカ、10065
        • Memorial Sloan-Kettering Cancer Center at Memorial Hospital
    • North Carolina
      • Durham、North Carolina、アメリカ、27710
        • Duke Cancer Center
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • University of Pennsylvania Perelman Center for Advanced Medicine
      • London、イギリス、NW1 2PG
        • University College London Hospital
      • Nottingham、イギリス、NG5 1PB
        • Nottingham City Hospital - Clinical Haematology
      • Oxford、イギリス、OX3 7LE
        • Churchill Hospital
      • Bergamo、イタリア、24127
        • ASST Papa Giovanni XXIII - Medicina Trasfusionale ed Ematologia - Bergamo
      • Bologna、イタリア、40138
        • A.O.di Bologna Policl.S.Orsola
      • Monza、イタリア、20900
        • PO San Gerardo, ASST Monza
      • Naples、イタリア、80131
        • Fondazione Pascale, IRCCS, Istituto Nazionale dei Tumori
      • Perugia、イタリア、06132
        • Ospedale S.Maria della Misericordia, AO di Perugia, Università degli Studi di Perugia
      • Leiden、オランダ、2333ZA
        • Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center)
      • Maastricht、オランダ、6229 HX
        • Universiteit Maastricht Academisch Ziekenhuis Maastricht
      • Richmond、オーストラリア、3121
        • Epworth Healthcare
      • Ottawa、カナダ、K1H 8L6
        • Ottawa Hospital Research Institute
      • Toronto、カナダ、M5G 1Z5
        • University Health Network Princess Margaret Hospital
    • British Columbia
      • Vancouver、British Columbia、カナダ、V5Z 4E6
        • BC Cancer - Vancouver Centre
      • Barcelona、スペイン、08029
        • ICO Hospital Duran i Reynals
      • Barcelona、スペイン、08035
        • Hospital Universitario Vall d'Hebrón
      • Madrid、スペイン、28040
        • Hospital Universitario Fundación Jiménez Díaz
      • Madrid、スペイン、28046
        • Hospital Universitario La Paz
      • Seville、スペイン、41013
        • Hospital Universitario Virgen del Rocio
      • Halle、ドイツ、06120
        • Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV
      • Dijon、フランス、21079
        • CHU de Dijon
      • Lille、フランス、59037
        • CHRU de Lille - Hôpital Claude Huriez - Maladies du Sang
      • Lyon、フランス、69008
        • Centre Lyon Berard - Medical Oncology
      • Paris、フランス、75010
        • APHP - Hopital Saint Louis
      • Paris、フランス、75015
        • Hôpital Necker
      • Pierre-Bénite、フランス、69495
        • Centre Hospitalier Lyon Sud - Hématologie
      • Toulouse、フランス、31100
        • Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)
      • Kaohsiung City、台湾、83301
        • Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology
      • Tainan、台湾、70403
        • National Cheng Kung University Hospital - Internal Medicine
      • Taipei、台湾、10002
        • National Taiwan University Hospital - Hematology And Oncology
      • Taoyuan City、台湾、33305
        • Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Hematology and Oncology - Hematology and Oncology
      • Fukuoka、日本、812-0054
        • Kyushu University Hospital
      • Kagoshima、日本、890-8520
        • Kagoshima University Hospital
      • Kyoto、日本、602-8566
        • University Hospital - Kyoto Prefectural University of Medicine
      • Nagasaki、日本、852-8501
        • Nagasaki University Hospital
      • Okayama、日本、700-8558
        • Okayama University Hospital
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、467-8602
        • Nagoya City University Hospital
      • Nagoya、Aichi-ken、日本、460-0001
        • National Hospital Organization Nagoya Medical Center - Hematology
    • Chiba
      • Kashiwa、Chiba、日本、277-8577
        • National Cancer Center Hospital East
    • Hokkaido
      • Sapporo、Hokkaido、日本、060-8648
        • Hokkaido University Hospital - Medical Oncology Center
    • Tokyo
      • Chuo Ku、Tokyo、日本、104-0045
        • National Cancer Center Hospital
      • Seoul、韓国、06591
        • The Catholic University of Korea, Seoul St. Mary's Hospital
      • Seoul、韓国、03080
        • Seoul National University Hospital - Department of Internal
      • Seoul、韓国、05505
        • Asan Medical Center - Oncology
      • Seoul、韓国、06351
        • Samsung Medical Center - Hematology-Oncology
    • Seoul Teugbyeolsi
      • Seoul、Seoul Teugbyeolsi、韓国、03722
        • Severance Hospital, Yonsei University Health System

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Written informed consent

  • Participants ≥18 years of age or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed.

  • Eastern Cooperative Oncology Group performance status of 0, 1, or 2

  • Cohort 1 relapsed/refractory peripheral T-cell lymphoma (PTCL):

    • Diagnosis should be confirmed by the local pathologist; local histological diagnosis will be used for eligibility determination. Participants with the following subtypes of PTCL are eligible according to 2016 WHO classification prior to the initiation of study drug. Any T-cell lymphoid malignancies not listed are excluded. Eligible subtypes include:

      • Enteropathy-associated T-cell lymphoma
      • Monomorphic epitheliotropic intestinal T-cell lymphoma
      • Hepatosplenic T-cell lymphoma
      • Primary cutaneous γδ T-cell lymphoma
      • Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
      • PTCL, not otherwise specified
      • Angioimmunoblastic T-cell lymphoma
      • Follicular T-cell lymphoma
      • Nodal PTCL with T-follicular helper (TFH) phenotype
      • Anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK) positive
      • ALCL, ALK negative
  • Cohort 2 relapsed/refractory adult T-cell leukemia/lymphoma (ATL) acute, lymphoma, or unfavorable chronic type. Relapsed/refractory ATL should be confirmed by the local pathologist; local diagnosis will be used for eligibility determination. The positivity of anti-human T-cell leukemia virus type 1 (HTLV-1) antibody will be locally determined for eligibility.

  • Must have at least one lesion which is measurable in 2 perpendicular dimensions on computed tomography (or magnetic resonance imaging) based on local radiological read

  • Documented refractory, relapsed, or progressive disease after at least 1 prior line of systemic therapy.

    • Refractory is defined as:

      • Failure to achieve complete response (CR) (or uncertified CR [CRu] for ATL) after first-line therapy
      • Failure to reach at least partial response (PR) after second-line therapy or beyond
  • Must have at least 1 prior line of systemic therapy for PTCL or ATL.

    • Participants must be considered hematopoietic cell transplantation (HCT) ineligible during screening due to disease status (active disease), comorbidities, or other factors; the reason for HCT ineligibility must be clearly documented.
    • In the PTCL cohort, participants with ALCL must have prior brentuximab vedotin treatment.

Exclusion Criteria:

Participants meeting any exclusion criteria for this study will be excluded from this study. Below is a list of the key exclusion criteria:

  • Diagnosis of mycosis fungoides, Sézary syndrome and primary cutaneous ALCL, and systemic dissemination of primary cutaneous ALCL

  • Diagnosis of precursor T-cell leukemia and lymphoma (T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma), T-cell prolymphocytic leukemia, or T-cell large granular lymphocytic leukemia

  • Prior malignancy active within the previous 2 years except for locally curable cancer that is currently considered as cured, such as cutaneous basal or squamous cell carcinoma, superficial bladder cancer, or cervical carcinoma in situ, or an incidental histological finding of prostate cancer.

  • Presence of active central nervous system involvement of lymphoma

  • History of autologous HCT within 60 days prior to the first dose of study drug

  • History of allogeneic HCT within 90 days prior to the first dose of study drug

  • Clinically significant graft-versus-host disease (GVHD) or GVHD requiring systemic immunosuppressive prophylaxis or treatment

  • Inadequate washout period from prior lymphoma-directed therapy before enrollment, defined as follows:

    • Prior systemic therapy (eg, chemotherapy, immunomodulatory therapy, or monoclonal antibody therapy) within 3 weeks prior or 5 half-lives of the drug, whichever is longer, to the first dose of study drug
    • Had curative radiation therapy or major surgery within 4 weeks or palliative radiation therapy within 2 weeks prior to the first dose of study drug
  • Uncontrolled or significant cardiovascular disease, including:

    • Evidence of prolongation of QT/QTc interval (eg, repeated episodes of QT corrected for heart rate using Fridericia's method >450 ms) (average of triplicate determinations)
    • Diagnosed or suspected long QT syndrome or known family history of long QT syndrome
    • History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes
    • Uncontrolled arrhythmia (subjects with asymptomatic, controllable atrial fibrillation may be enrolled) or asymptomatic persistent ventricular tachycardia
    • Participant has clinically relevant bradycardia of <50 bpm, unless the participant has a pacemaker
    • History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers within 6 months prior to Screening
    • Myocardial infarction within 6 months prior to Screening
    • Angioplasty or stent craft implantation within 6 months prior to Screening
    • Uncontrolled angina pectoris within 6 months prior to Screening
    • New York Heart Association Class 3 or 4 congestive heart failure
    • Coronary/peripheral artery bypass graft within 6 months prior to Screening
    • Uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg)
    • Complete left bundle branch block
  • History of treatment with other EZH inhibitors

  • Current use of moderate or strong cytochrome P450 (CYP)3A inducers

  • Systemic treatment with corticosteroids (>10 mg daily prednisone equivalents). Note: Short-course systemic corticosteroids (eg, prevention/treatment for transfusion reaction) or use for a non-cancer indication (eg, adrenal replacement) is permissible.

  • Known or suspected hypersensitivity to valemetostat tosylate or any of the excipients

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma

Participants who will receive 200 mg/day valemetostat tosylate and had an eligible peripheral T-cell lymphoma subtype that was confirmed by independent hematopathology central review.

Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity

他の名前:
  • DS-3201b
実験的:Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma

Participants who will receive 200 mg/day valemetostat tosylate and had an eligible adult T-cell leukemia/lymphoma subtype that was confirmed by the local pathologist/investigators and by documented positive anti-human T-cell leukemia virus type 1 (HTLV-1) antibody.

Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity

他の名前:
  • DS-3201b

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants With Objective Response As Assessed by Blinded Independent Central Review After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)
時間枠:From baseline until disease progression or death (whichever occurs first), up to approximately 23 months

For the relapsed/refractory peripheral T-cell lymphoma (PTCL) cohort, objective response rate (ORR) is defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), assessed by blinded independent central review (BICR), among participants with centrally confirmed PTCL eligible histology.

From baseline until disease progression or death (whichever occurs first), up to approximately 23 months
Number of Participants With Treatment-emergent Adverse Events After Administration of Valemetostat Tosylate Monotherapy (Cohort 2)
時間枠:From the time the informed consent form is signed up to 30 days after last dose, up to 23 months

Treatment-emergent adverse events (TEAEs) were defined as new AEs or pre-existing conditions that worsen in National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade after the first dose of study drug and up to 30 days after the last dose of study drug.

From the time the informed consent form is signed up to 30 days after last dose, up to 23 months

二次結果の測定

結果測定
メジャーの説明
時間枠
バレメトスタットトシル酸塩単剤療法の投与後に治療中に発現した有害事象が発生した参加者の数(コホート1)
時間枠:インフォームドコンセントフォームに署名した時点から、最後の投与後 30 日以内まで
インフォームドコンセントフォームに署名した時点から、最後の投与後 30 日以内まで
Plasma Concentrations of DS-3201a and CALZ-1809a After Administration of Valemetostat Tosylate Monotherapy
時間枠:Cycle 1 Day 1, 8, 15 Predose; Cycle 1 Day 1 (1, 2, 4, 5 hours Postdose); Cycle 2 Day 1 Predose; Cycle 3 Day 1 to Cycle 5 Day 1 Predose (each cycle is 28 days)

Total and unbound DS-3201a (free form of valemetostat tosylate) and total CALZ-1809a (major metabolite) concentration in plasma will be assessed.

Cycle 1 Day 1, 8, 15 Predose; Cycle 1 Day 1 (1, 2, 4, 5 hours Postdose); Cycle 2 Day 1 Predose; Cycle 3 Day 1 to Cycle 5 Day 1 Predose (each cycle is 28 days)
Duration of Response After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)
時間枠:Time from the date of first documented response (CR or PR) until documented disease progression (progressive or relapsed disease) based on BICR assessments or death from any cause (whichever occurs first), up to approximately 56 months

Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (CR or PR) to the date of the first documentation of disease progression (progressive or relapsed disease) based on BICR assessments or to death due to any cause, whichever occurs first.

Time from the date of first documented response (CR or PR) until documented disease progression (progressive or relapsed disease) based on BICR assessments or death from any cause (whichever occurs first), up to approximately 56 months
Percentage of Participants With Complete Response After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)
時間枠:From baseline to date of first documented objective response of CR, up to approximately 56 months

Complete response rate is the percentage of participants achieving CR as the BOR based on BICR assessments.

From baseline to date of first documented objective response of CR, up to approximately 56 months
Duration of Complete Response After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)
時間枠:Time from the date of first documented CR until documented disease progression (progressive or relapsed disease) based on BICR assessments or death from any cause (whichever occurs first), up to approximately 56 months

Duration of complete response is defined as the time from the date of the first documentation of CR to the date of the first documentation of disease progression (progressive or relapsed disease) based on BICR assessments or to death due to any cause, whichever occurs first.

Time from the date of first documented CR until documented disease progression (progressive or relapsed disease) based on BICR assessments or death from any cause (whichever occurs first), up to approximately 56 months
Percentage of Participants With Partial Response After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)
時間枠:From baseline to date of first documented objective response of PR, up to approximately 56 months

Partial response rate is the percentage of participants achieving PR as the BOR based on BICR assessment.

From baseline to date of first documented objective response of PR, up to approximately 56 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Global Clinical Leader、Daiichi Sankyo

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年6月3日

一次修了 (実際)

2023年5月10日

研究の完了 (推定)

2029年6月19日

試験登録日

最初に提出

2021年1月7日

QC基準を満たした最初の提出物

2021年1月7日

最初の投稿 (実際)

2021年1月11日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月6日

QC基準を満たした最後の更新が送信されました

2026年10月23日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • DS3201-A-U202
  • 2020-004954-31 (EudraCT番号)
  • 2023 (米国 NIH グラント/契約)
  • jRCT2071200095 (その他の識別子:jRCT)
  • 2023-507381-13-00 (Ctis)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

IPD 共有時間枠

Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

IPD 共有アクセス基準

Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。